You’re offline. This is a read only version of the page.
EnteroBiotix
James McIlroy is the founder and CEO of EnteroBiotix a patient-centred biotechnology company developing novel medicinal products for use in infections or diseases associated with imbalances of bacteria in the human gut.
He first took an interest in entrepreneurship during his third year of medical school when he identified an unmet clinical need for safe access to Faecal Microbiota Transplantation(FMT) - a medical treatment that involves the transfer of bacteria from a healthy person’s gut into the gut of someone suffering from disease. James was just 21 years old when he co-founded his first company to try and solve this problem.
Following on from his Converge win in 2015, James was awarded a place on The Royal Society Edinburgh’s coveted Enterprise Fellowship programme and has also received support from the University of Aberdeen and Scottish EDGE.
“I cannot praise highly enough the Converge training and support provided to me by the team that enabled me to progress my company at such a crucial stage.”
In 2017, EnteroBiotix raised £500,000 in an oversubscribed round of investment. James has also received many awards for his entrepreneurial achievements, including Young Pioneer of Year by Herald Scotland, Ten Outstanding Young People in Scotland by Junior Chamber International, and Emerging Entrepreneur (Scotland) by BQ Magazine.
James is currently undertaking his final year of medical school the University of Aberdeen alongside his role as CEO. In 2018, he plans to graduate as a doctor and continue his training. EnteroBiotix plans secure various licenses that will allow the company to begin releasing its products for patient use and investigational clinical trials. To meet these goals, James intends on expanding the core team, currently at 7, to 14.